A second CAR-T cell therapy from Bristol Myers Squibb that is under review at the European Medicines Agency has lost its fast-track status.
Lisocabtagene maraleucel (liso-cel) reverted to standard review timelines a couple of months ago and now idecabtagene vicleucel (ide-cel), from BMS...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?